When Cannabis Use May Require Extra Caution Before GLP-1 Therapy Cannabis use may require extra caution when symptoms already involve vomiting, poor intake, sedation, abnormal digestion, or blood sugar risk
Tirzepatide maintenance: the SURMOUNT-4 evidence The SURMOUNT-4 trial used a randomized-withdrawal design: all participants took open-label tirzepatide for 36 weeks (reaching a mean weight reduction of about 20.9%), then were randomized either to continue the drug or switch to placebo for another 52 weeks
Whats the same All four mimic GLP-1
Source: FDA FDA Warns Patients and Health Care Professionals Not to Use Compounded Drugs from Fullerton Wellness November 1, 2024 -- FDA is warning patients and health care professionals not to use drugs compounded and distributed by Fullerton Wellness LLC, Ontario, Calif., and distributed to patients by medical offices and clinics Fullerton Wellness is a facility that compounds drugs intended to be sterile, including semaglutide and tirzepatide injections
If you suspect this is what you're experiencing chronic fatigue, central weight gain, reduced exercise tolerance, low mood the right step is a GP referral, not a vial off the internet